Clinical Trial Update: Pilot Study to Assess Safety, Preliminary Efficacy and Pharmacokinetics of S.C. Pegcetacoplan (APL-2) in PNH Subjects. [Phase 1]

View source ↗

Summary

Pilot Phase 1 trial evaluating safety, preliminary efficacy, and pharmacokinetics of subcutaneous pegylated complement inhibitor pegcetacoplan (APL-2) in paroxy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• Pegcetacoplan (Pegcetacoplan)

Snippet

Sponsor: Apellis Pharmaceuticals, Inc. | Conditions: Paroxysmal Nocturnal Hemoglobinuria | Phase 1 | Status: COMPLETED | Results posted: 2021-01-11